PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the short-term efficacy of Dutasteride in the management of chronic prostatitis (CP)/chronic pelvic pain syndrome.
UNASSIGNED: A randomized placebo-controlled double-blind study was conducted that including 50 patients diagnosed with CP based on the presence of pelvic pain for ≥3 months of the preceding 6 months. Patients were randomized into 2 equal groups to evaluate Dutasteride of 0.5 mg once daily that was given for 3 months compared to a placebo.
UNASSIGNED: Forty-nine patients were evaluated after the follow-up period with no statistically significant difference in the perioperative demographic data. The mean age of the Dutasteride group was 48.3 (range 41-62) compared to a mean age of 46.5 (range 44-60) in the placebo group. There was a highly statistically significant improvement in the Dutasteride group compared to its preoperative parameters and the placebo compared group in the terms of pain, urinary scores, and total National Institutes of Health CP symptom score. Moderate and marked improvement in patients\' symptomatology was seen in 56% of the dutasteride group, while only 8% in the dutasteride group failed to show an improvement with no significant side effects noted in our study.
UNASSIGNED: The short-term outcome of dutasteride therapy showed an improvement in the National Institutes of Health-CP symptom score compared to a placebo in the treatment of category IIIB CP.
UNASSIGNED: NCT04756206.
UNASSIGNED: A randomized placebo-controlled double-blind study was conducted that including 50 patients diagnosed with CP based on the presence of pelvic pain for ≥3 months of the preceding 6 months. Patients were randomized into 2 equal groups to evaluate Dutasteride of 0.5 mg once daily that was given for 3 months compared to a placebo.
UNASSIGNED: Forty-nine patients were evaluated after the follow-up period with no statistically significant difference in the perioperative demographic data. The mean age of the Dutasteride group was 48.3 (range 41-62) compared to a mean age of 46.5 (range 44-60) in the placebo group. There was a highly statistically significant improvement in the Dutasteride group compared to its preoperative parameters and the placebo compared group in the terms of pain, urinary scores, and total National Institutes of Health CP symptom score. Moderate and marked improvement in patients\' symptomatology was seen in 56% of the dutasteride group, while only 8% in the dutasteride group failed to show an improvement with no significant side effects noted in our study.
UNASSIGNED: The short-term outcome of dutasteride therapy showed an improvement in the National Institutes of Health-CP symptom score compared to a placebo in the treatment of category IIIB CP.
UNASSIGNED: NCT04756206.
摘要：
UNASSIGNED：评估度他雄胺治疗慢性前列腺炎（CP）/慢性盆腔疼痛综合征的短期疗效。
UNASSIGNED：进行了一项随机安慰剂对照双盲研究，包括50名在过去6个月中因盆腔疼痛≥3个月被诊断为CP的患者。患者被随机分为2个相等的组，以评估与安慰剂相比每天给予0.5mg的度他雄胺，每天给予3个月。
UNASSIGNED：在随访期后对49例患者进行了评估，围手术期人口统计学数据无统计学差异。Dutasteride组的平均年龄为48.3（范围41-62），而安慰剂组的平均年龄为46.5（范围44-60）。在疼痛方面，与术前参数和安慰剂对照组相比，度他雄胺组有高度统计学意义的改善，尿评分,和美国国立卫生研究院CP症状总评分。在56%的度他雄胺组中，患者的症状有中度和显著的改善，而在我们的研究中，只有8%的度他雄胺组未显示出改善，没有明显的副作用。
UNASSIGNED：在IIIB类CP治疗中，与安慰剂相比，度他雄胺治疗的短期结果显示，美国国立卫生研究院CP症状评分有所改善。
未经评估：NCT04756206。
UNASSIGNED：进行了一项随机安慰剂对照双盲研究，包括50名在过去6个月中因盆腔疼痛≥3个月被诊断为CP的患者。患者被随机分为2个相等的组，以评估与安慰剂相比每天给予0.5mg的度他雄胺，每天给予3个月。
UNASSIGNED：在随访期后对49例患者进行了评估，围手术期人口统计学数据无统计学差异。Dutasteride组的平均年龄为48.3（范围41-62），而安慰剂组的平均年龄为46.5（范围44-60）。在疼痛方面，与术前参数和安慰剂对照组相比，度他雄胺组有高度统计学意义的改善，尿评分,和美国国立卫生研究院CP症状总评分。在56%的度他雄胺组中，患者的症状有中度和显著的改善，而在我们的研究中，只有8%的度他雄胺组未显示出改善，没有明显的副作用。
UNASSIGNED：在IIIB类CP治疗中，与安慰剂相比，度他雄胺治疗的短期结果显示，美国国立卫生研究院CP症状评分有所改善。
未经评估：NCT04756206。
